New PET scan probe could sharpen lung cancer detection

NCT ID NCT07508852

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and the new PFD3 scan to compare their accuracy. The goal is to improve diagnosis and monitoring of this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-PFD3 (a radioactive probe for PET/CT imaging)
What this could lead to: If successful, this could provide a more accurate way to diagnose and monitor small cell lung cancer, potentially guiding better treatment decisions.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The probe's safety and effectiveness are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC SCLC, EXTENSIVE STAGE SCLC, LIMITED STAGE SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER ( SCLC )

Contacts and locations

Locations

Peking university first hospital nuclear medicine
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.